Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Santen Pharmaceutical Co's Operating Income for the
three
months ended in Jun. 2026 was MXN881 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was MXN5,579 Mil.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Santen Pharmaceutical Co's annualizedROC % for the quarter that ended in Jun. 2026 was 9.06%.
Santen Pharmaceutical Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 25.69%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Be Aware
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Santen Pharmaceutical Co Operating Income Related Terms
Santen Pharmaceutical Co Operating Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co Operating Income Calculation
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN5,579 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Income of MXN5,579 Mil mean?
Santen Pharmaceutical Co (MEX:4536N) has a Operating Income of MXN5,579 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Operating Income too high?
Santen Pharmaceutical Co's current Operating Income is MXN5,579 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Operating Income compare to LLY and JNJ?
Santen Pharmaceutical Co's Operating Income of MXN5,579 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Operating Income is MXN5,579 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Santen Pharmaceutical Co (MEX:4536N) has a current Operating Income of MXN5,579 Mil. The stock's GF Value™ is MXN299.21, compared to a current price of MXN339.23 — trading 13.4% above its estimated fair value. The current Operating Income is MXN5,579 Mil. Santen Pharmaceutical Co's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Santen Pharmaceutical Co (MEX:4536N), the current Operating Income is MXN5,579 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (MEX:4536N) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of MXN339.23 is trading 13.4% above its estimated GF Value™ of MXN299.21.
Key valuation signals for MEX:4536N:
Operating Income: MXN5,579 Mil
GF Value™: MXN299.21 vs. price of MXN339.23 (13.4% above fair value)
No single metric tells the full story. See the MEX:4536N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
80GF Score
Get the complete analysis for MEX:4536N
Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:4536N has been successfully added to your 
